Reduction of hepatotoxicity of tumor necrosis factor in isolated hepatic perfusion by administration of glucocorticoid as well as lipopolysaccharide

Anticancer Research

Volumn 20, Issue 1 C, 2000, Pages 623-628

  Nakamoto, Takeru ^a,b   Inagawa, Hiroyuki ^a   Takagi, Koichi ^a   Tashiro, Kazuhiro ^a   Yoshimura, Hiroshi ^a   Nishizawa, Takashi ^a   Honda, Teruko ^a   Kanou, Junko ^a   Muto, Yoshihiro ^b   Soma, Gen Ichiro ^a  

^a TAKANO HOSPITAL   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Intradermal administration; Isolation; Liver; LPS; Metastasis; Perfusion; TNF SAM2

Indexed keywords

DEXAMETHASONE; FLUOROURACIL; GLUCOCORTICOID; LIPOPOLYSACCHARIDE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; DRUG TOLERABILITY; ISOLATED LIVER; LIVER HISTOLOGY; LIVER NECROSIS; LIVER PERFUSION; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADULT; ANIMALS; DEXAMETHASONE; HUMANS; LIPOPOLYSACCHARIDES; LIVER; MALE; MIDDLE AGED; RATS; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034108912     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Liénard D, Ewalenko P, Delmotti JJ, et al: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60, 1992.
2. Fraker DL, Alexander HR: The use of tumor necrosis factor in isolated limb perfusions for melanoma and sarcoma. In: Principles and Practice of Oncology (DeVita V, Hellman S and Rosenberg SA, eds). Philadelphia, PA Lippincott, 1993, pp 329-346.
3. Alexander HR, Fraker DL, Bartlett DL: Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 12: 416-428, 1996.
4. Alexander HR, Barlett D, Libutti S, et al: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16: 1479-1489, 1998.
5. Fraker DL, Alexaner HR, Thorn AK: Use of tumor necrosis factor in isolated hepatic perfusion. Circ Shock 44: 45-50, 1994.
6. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107: 459-465, 1987.
7. Rougier P, Laplanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10: 1112-1118, 1992.
8. Nakamoto T, Inagawa H, Takagi T, et al: Pharmacokinetics of isolated hepatic perfusion with high dose tumor necrosis factor in rat model. Anticancer Res (in press).
9. Nishizawa T, Inagawa H, Oshima H, et al: Homeostasis as regulated by activated macrophage. I. Lipopolysaccharide from wheat flour: Isolation, purification and some biological activities. Chem Pharm Bull 40: 479-483, 1992.
10. Inagawa H, Nishizawa T, Tsukioka D, et al: Homeostasis as Regulated by Activated Macrophage. II. LPS of Plant Origin Other than Wheat Flour and Their Concomitant Bacteria. Chem Pharm Bull 40: 494-997, 1492.
11. Soma G-I, Tsuji Y, Tanabe Y, et al: Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells. J Biol Resp Modif 7: 587-595, 1988.
12. Ruff MR, Gifford GE: Purification and physicochemical characterization of rabbit tumor necrosis factor. J Immunol 125: 1671-1677, 1980.
13. Gatanaga T, Takahashi T, Yamazaki M, et al: Combination antitumor therapy with rabbit tumor necrosis factor and chemo- and immunotherapeutic agents against murine tumors. Jpn J Cancer Res 76: 631-636, 1985.
14. Treffers HP: The linear representation of dosage-response curves in microbial-antibiotic assay. J Bacteriol 72: 108-114, 1956.
15. de Brauw LM, van de Velde CJ, Tjaden UR, et al: In vivo isolated liver perfusion technique in a rat hepatic metastasis model: 5-fluorouracil concentrations in tumor tissue. J Surg Res 44: 137-145. 1988.
16. Lejeune F, Liénard D, Eggermont A: Clinical Experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circ Shock 43: 191-197, 1944.
17. Kahky MP, Daniel CO, Curz AB: Portal infusion of tumor necrosis factor increases mortality in rats. J Surg Res 49: 138-145, 1940.
18. Gatanaga T, Noguchi K, Tanabe Y, et al: Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-α in vivo. J Biol Resp Modif 8: 278-286, 1989.
19. Colletti LM, Remick DG, Campbell DA Jr: LPS pretreatment protection from hepatic ischemia/reperfusion. J Sur Res 57: 337-343, 1994.
20. Zwaveling JH, Maring JK, Moshage H, et al: Role of nitric oxide in recombinant tumor necrosis factor-alpha-induced circulatory shock: a study in patients treated for cancer with isolated limb perfusion. Crit Care Med 24: 1806-1810, 1996.
21. Abe S, Yamamoto T, Iihara S, et al: A possible role of glucocorticoids: an intrinsic inhibitor of the cytotoxic activity of tumor necrosis factor. Jpn J Cancer Res 79: 305-308, 1988.
22. Schneider J, Bruckmann W, Zwingenberger K: Extravasation of leukocytes assessed by intravital microscopy: effect of thalidomide. Inflamm Res 46: 392-397, 1997.
23. Tsujimoto M, Okamura N, Adachi H: Dexamethasone inhibits the cytotoxic activity of tumor necrosis factor. Biochcm Biophys Res Commun 153: 109-115, 1988.
24. Inagawa H, Nishizawa T, Noguchi K, et al: Anti-tumor effect of lipopolysaccharide by intradermal administration as novel drug delivery system. Anticancer Res 17: 2153-2158, 1997.
25. Mizuno D, Yoshioka O, Akamatsu M, et al: Antitumor effect of intracutaneous injection of bacterial lipopolysaccharide. Cancer Res 28: 1531-1537, 1968.
26. Goto S, Sakai S, Kera J, et al: Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol Immunother 42: 255-261, 1996.
27. Chun M, Hoffmann MK: Combination immunotherapy of cancer in a mouse model: synergism between tumor necrosis factor and other defense systems. Cancer Res 47: 115-118, 1987.
28. DeForge LE, Kenney JS, Jones ML, et al: Biphasic production of 1L-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS- and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-1 antibodies. J Immunol 148: 2133-2141, 1992.
29. Vogel SN, Kaufman EN, Tate MD, et al: Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes. Infect Immun 56: 2650-2657, 1988.
30. Neta R, Douches SD, Oppenheim JJ: Interleukin 1 is a radioprotector. J Immunol 136: 2483-2485, 1986.
31. Gahring LC, Daynes RA: Desensitization of animals to the inflammatory effects of ultraviolet radiation is mediated through mechanisms which are distinct from those responsible for endotoxin tolerance. J Immunol 136: 2868-2874, 1986.
32. Ohno S, Strebel FR, Stephens LC, et al: Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats. Cancer Res 52: 4096-4101, 1992.
33. Tomita A, Fuchino Y, Otsuka K, et al: Clinical effects of exogenous/ endogenous TNF therapy on melastatic lesions of 34 colorectal cancer patients. Anticancer Res 18: 3937-3939, 1998.
34. Krosnick JA, Mule JJ, McIntosh JK, et al: Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in viro. Cancer Res 49: 3729-3733, 1989.
35. Lev-Chelouche D, Abu-Abeid S, Kollander Y, et al: Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. J Surg Oncol 70: 185-189, 1999.
36. Manusama ER, Nooijen PT, Stavast J, et al: Synergistic antitumor effect of recombinant human tumor nerosis factor with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551-555, 1996.